证券代码：300003 证券简称：乐普医疗 公告编号：2025-053 乐普（北京）医疗器械股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次权益分派期间，公司可转换公司债券乐普转 2（债券代码：123108） 已暂停转股，截至本公告披露日，公司总股本为 1,880,611,251 股。 1、乐普（北京）医疗器械股份有限公司（以下简称：公司）2024 年年度权 益分派方案经 2025 年 5 月 15 日召开的 2024 年年度股东大会审议通过； 2、自本次权益分派方案披露至实施期间，公司总股本因可转换公司债券乐 普转 2 部分转股而发生变动，截至本公告披露日，公司总股本由 2025 年 3 月 31 日的 1,880,611,082 股增至 1,880,611,251 股； 3、本次实施的权益分配方案与公司股东大会审议通过的方案一致； 4、本次实施权益分派方案距离股东大会审议通过的时间未超过两个月。 1 二、权益分派方案 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》"第二 ...

| 证券代码：300003 | 证券简称：乐普医疗 | 公告编号：2025-054 | | --- | --- | --- | | 债券代码：123108 | 债券简称：乐普转 2 | | 乐普（北京）医疗器械股份有限公司 关于可转债乐普转 2 转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 债券代码：123108 债券简称：乐普转 2 调整前"乐普转 2"转股价格为：27.92 元/股 调整后"乐普转 2"转股价格为：27.79 元/股 转股价格调整生效日期：2025 年 6 月 20 日 一、转股价格调整的相关规定 经中国证券监督管理委员会出具的《关于同意乐普（北京）医疗器械股份有 限公司向不特定对象发行可转换公司债券注册的批复》（证监许可〔2021〕741 号）核准，乐普（北京）医疗器械股份有限公司（以下简称"公司"）于 2021 年 3 月 30 日向不特定对象发行了 1,638.00 万张可转换公司债券（以下简称"可 转债"），每张面值 100 元，发行总额 163,800.00 万元。 根据《乐普（北京）医疗器械股份 ...

Core Insights - The total margin financing balance for the ChiNext market reached 344.136 billion yuan, marking a continuous increase for six trading days, with a cumulative increase of 5.784 billion yuan during this period [1][2]. Margin Financing Balance Overview - As of June 10, 2025, the total margin financing balance was 345.070 billion yuan, with an increase of 0.321 billion yuan from the previous trading day [2]. - The margin financing balance specifically was 344.136 billion yuan, which increased by 0.342 billion yuan from the previous day [2]. Individual Stock Performance - During the period of increasing margin financing, 559 stocks saw an increase in their financing balances, with 56 stocks experiencing an increase of over 20% [2]. - The stock with the highest increase in financing balance was Dahongli, which saw an increase of 111.16%, bringing its latest financing balance to 56.0291 million yuan [3]. - Conversely, 374 stocks experienced a decrease in their financing balances, with 42 stocks declining by over 10%. The largest decrease was seen in Lulian Technology, which dropped by 38.36% [3]. Sector Performance - Stocks with financing balance increases of over 20% were primarily concentrated in the pharmaceutical, machinery, and basic chemical industries, with 14, 7, and 7 stocks respectively [5]. Market Performance - Stocks with financing balance increases of over 20% averaged a rise of 12.00%, outperforming the ChiNext index. Notable gainers included Kangli Source, Changshan Pharmaceutical, and Xice Testing, with increases of 64.82%, 34.93%, and 33.42% respectively [5]. - The largest increases in financing balances by amount were recorded by Sifang Jingchuang (1.305 billion yuan), followed by Juguang Technology (300 million yuan) and Lepu Medical (252 million yuan) [5].

证券代码：300003 证券简称：乐普医疗 公告编号：2025-052 债券代码：123108 债券简称：乐普转 2 乐普（北京）医疗器械股份有限公司 关于权益分派期间乐普转 2 暂停转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 债券代码：123108 债券简称：乐普转 2 转股起止时间：2021 年 10 月 8 日至 2026 年 3 月 29 日 暂停转股时间：2025 年 6 月 12 日至 2024 年度权益分派股权登记日 恢复转股时间：公司 2024 年度权益分派股权登记日后的第一个交易日 乐普（北京）医疗器械股份有限公司（以下简称：公司）将于近日实施 2024 年度权益分派，根据《乐普（北京）医疗器械股份有限公司创业板向不特定对象 发行可转换公司债券募集说明书》中"转股价格的调整方式"条款的规定（详见 附件），自 2025 年 6 月 12 日起至本次 2024 年度权益分派股权登记日止，公司 可转换公司债券乐普转 2（债券代码：123108；债券简称：乐普转 2）将暂停转 股，公司将在本次权益分派股权登记日后的第 ...

Company Overview - Lepu Medical's closing price on June 10 was 13.47 yuan, with an increase of 4.10%, resulting in a rolling price-to-earnings (PE) ratio of 176.40 times and a total market capitalization of 25.332 billion yuan [1] - The company's main business includes medical devices, pharmaceuticals, medical services, and health management [1] Financial Performance - In the first quarter of 2025, Lepu Medical reported operating revenue of 1.736 billion yuan, a year-on-year decrease of 9.67%, and a net profit of 379 million yuan, down 21.44% year-on-year, with a gross profit margin of 64.03% [1] Industry Comparison - The average PE ratio for the medical device industry is 51.00 times, with a median of 37.03 times, placing Lepu Medical at the 113th position in the industry ranking [1][2] - The industry average market capitalization is 10.870 billion yuan, while the median is 4.980 billion yuan [2] Capital Flow - On June 10, Lepu Medical experienced a net inflow of main funds amounting to 176.6142 million yuan, with a total inflow of 174.9574 million yuan over the past five days [1]

Group 1: Market Performance - The weight loss drug concept index rose by 1.46%, ranking 7th among concept sectors, with 27 stocks increasing in value [1] - Notable gainers included Zhongsheng Pharmaceutical, which hit the daily limit, and Hanyu Pharmaceutical, Yipinhong, and Tianenkang, with increases of 13.58%, 9.40%, and 9.35% respectively [1] - The sector experienced a net outflow of 600 million yuan in capital, with 23 stocks seeing net inflows, and 6 stocks receiving over 30 million yuan in net inflows [2] Group 2: Capital Flow - Leading the net inflow of capital was Lepu Medical, with a net inflow of 176 million yuan, followed by Hengrui Medicine and Ganli Pharmaceutical with net inflows of 164 million yuan and 117 million yuan respectively [2] - The top three stocks by net inflow ratio were Kexing Pharmaceutical, Lepu Medical, and Ganli Pharmaceutical, with net inflow ratios of 9.86%, 9.24%, and 8.74% respectively [3] Group 3: Stock Performance - The stock performance table indicated that Lepu Medical had a daily increase of 4.10% with a turnover rate of 8.77%, while Hengrui Medicine rose by 1.42% with a turnover rate of 0.75% [3] - Other notable performers included Tianenkang with a 9.35% increase and a turnover rate of 10.42%, and Kexing Pharmaceutical with a 6.40% increase and a turnover rate of 3.35% [4]

Group 1 - Medical device sector shows strong performance with ETF fund (159797) experiencing significant trading volume and net inflow of funds [1] - Recent policy document issued on June 9 aims to improve healthcare resources and insurance mechanisms, which is seen as a major driver for pharmaceutical companies [3] - Citic Securities predicts a trend of low-to-high earnings growth in the medical device sector, with significant improvements expected in the second half of the year [4] Group 2 - Structural investment opportunities exist within the medical device sector, with certain companies expected to achieve high growth in Q2 and Q3 [5] - The easing of US-China tariffs is beneficial for medical device companies, potentially lowering production costs and expanding overseas market share [6] - The medical device ETF fund (159797) covers core areas such as medical equipment and in vitro diagnostics, with top ten weighted stocks accounting for 46.78% [6][7]

Core Viewpoint - Lepu Medical's self-developed polylactic acid facial filler has received approval from the National Medical Products Administration (NMPA), marking its entry into the regenerative aesthetic market, despite ongoing performance declines [1][2][4] Product Approval and Market Position - The approved product is the seventh domestic and fifth local "youthful needle" filler, indicating a significant step into the aesthetic medicine sector [1] - The product is classified as a Class III medical device, which has a high approval threshold, positioning the company in the second tier among domestic products [2] - The regenerative aesthetic filler market in China is projected to reach 11.52 billion yuan by 2027, with a compound annual growth rate of 31.2% [2] Product Pipeline and Strategy - Lepu Medical's aesthetic pipeline includes botulinum toxin type A and various hyaluronic acid formulations, creating a comprehensive product chain covering "regenerative filling - wrinkle repair - facial shaping" [1][2] - The company is expanding its aesthetic product line, with multiple hyaluronic acid products in the registration phase and a focus on maintaining core technology autonomy to control costs and build brand barriers [4][5] Financial Performance and Challenges - Lepu Medical's financial performance has been under pressure, with a 23.52% decline in revenue to 6.103 billion yuan in 2024 and an 80.37% drop in net profit to 247 million yuan, marking the worst performance since its listing in 2009 [6] - The core business segments, including medical devices and pharmaceuticals, have faced significant revenue declines, with the medical device segment down 9.47% and pharmaceuticals down 42.25% [6] Management Changes and Strategic Shift - The company has undergone management changes, with a new general manager implementing marketing reforms and workforce reductions to enhance operational efficiency [7] - The shift towards aesthetic medicine is seen as a strategic response to pressures from traditional pharmaceutical operations, with the potential for financial recovery hinging on successful product commercialization and market adaptation [7]

Core Insights - The medical beauty materials market is entering a competitive phase in 2025, with significant approvals for new materials such as agarose and hydroxyapatite, indicating a growing diversity of products [1][10] - The approval of various injection fillers, including recombinant collagen and animal-derived collagen, highlights the rapid development and commercialization of medical beauty materials [1][4] - Investment in medical beauty materials companies has surged, with 12 companies securing funding in the first five months of 2025, reflecting strong interest from investors [4][5] Regulatory Approvals - Hydroxyapatite received two approvals in 2025, with the first compliant product for medical beauty injections approved in February [10] - Agarose also saw its first approval in January 2025, marking a significant milestone for this material in the domestic market [10] - Over 110 products for medical beauty injections have been approved in China, primarily classified as Class III medical devices [2][4] Market Dynamics - The competition for the first regulatory approval (Class III certificate) is intense, as it provides a significant market advantage [10][12] - Companies are increasingly focusing on developing new materials and applications, with many aiming to secure the first approval in various new material categories [11][12] - The market is characterized by a mix of established companies and startups, all vying for a share of the growing medical beauty sector [15][16] Investment Trends - Notable investments in medical beauty materials companies include significant funding rounds for firms like 聚源生物 and 未名拾光, indicating robust investor confidence [5][6] - The trend of startups receiving funding is expected to continue, as the demand for innovative medical beauty solutions grows [4][5] Product Development - Companies are exploring the combination of different materials to enhance product competitiveness, with a focus on safety and efficacy [14][15] - New materials such as PDRN, silk protein, and chitosan are being investigated for their applications in medical beauty and functional skincare [16][17] - The development of multi-indication products is becoming a strategic focus, with companies aiming to address various aesthetic needs [13][15] Future Outlook - The medical beauty market is anticipated to expand, driven by the introduction of new materials and innovative applications [16][17] - The interplay between medical beauty and skincare sectors is expected to create a positive feedback loop, enhancing market growth [16][17] - Ultimately, the success of new materials will depend on their clinical validation and real-world application, as safety and effectiveness remain paramount [16][17]

Core Viewpoint - Lepu Medical has received approval from the National Medical Products Administration for its self-developed polylactic acid facial filler, marking its entry into the dermatology field and aiming to boost its consumer healthcare business [1] Group 1: Company Developments - Lepu Medical has shifted focus from generic drugs to innovative cardiovascular drugs and dermatology injection products due to declining performance [1] - The company reported a significant decline in revenue and net profit, with 2023 revenue at 7.98 billion yuan, down 24.78%, and net profit at 1.26 billion yuan, down 42.91% [5] - In 2024, Lepu Medical's revenue further decreased to 6.103 billion yuan, a 23.52% decline, and net profit dropped to 247 million yuan, down 80.37% [5] - The company has also expanded its product line in dermatology with several injection products, including sodium hyaluronate solutions [4] Group 2: Market Competition - The global market for facial fillers, known as "童颜针," is projected to reach approximately $1.488 billion in 2024, growing to $1.5445 billion in 2025, with a compound annual growth rate of 3.8% from 2025 to 2033 [2] - The domestic market for "童颜针" is expected to exceed 3 billion yuan by 2024, up from about 100 million yuan in 2021 [2] - Competition in the "童颜针" market is intensifying, with six other products already approved prior to Lepu Medical's entry, including both domestic and imported options [2] Group 3: Financial Performance and Future Outlook - Lepu Medical's first quarter of 2025 continued the trend of declining performance, with revenue of 1.736 billion yuan, down 9.67%, and net profit of 379 million yuan, down 21.44% [6] - The company anticipates future profit growth primarily from structural heart disease, dermatology, and neuro-regulation sectors, while traditional medical device products are expected to maintain around 10% revenue growth [6] - The impact of the newly approved dermatology product on Lepu Medical's future performance remains uncertain [3]